All patients with CALR mutations were diagnosed either as ET (n = 32, 65%) or PMF (n = 17, 35%), and the median CALR mutant burden was significantly higher in patients with PMF than in those with ET (45% vs. 34%, p = 0.001). This evidence concerns the gene CALR and essential thrombocythemia.